Acute Pain - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：180頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Acute Pain - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Acute Pain - Pipeline Review, H1 2014’, provides an overview of the Acute Pain’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Acute Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Pain and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Acute Pain
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Acute Pain and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Acute Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acute Pain pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acute Pain
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acute Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Acute Pain - Pipeline Review, H1 2014’, provides an overview of the Acute Pain’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Acute Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Pain and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Acute Pain
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Acute Pain and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Acute Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acute Pain pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acute Pain
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acute Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Acute Pain Overview 9
Therapeutics Development 10
Pipeline Products for Acute Pain - Overview 10
Pipeline Products for Acute Pain - Comparative Analysis 11
Acute Pain - Therapeutics under Development by Companies 12
Acute Pain - Therapeutics under Investigation by Universities/Institutes 16
Acute Pain - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Acute Pain - Products under Development by Companies 21
Acute Pain - Products under Investigation by Universities/Institutes 24
Acute Pain - Companies Involved in Therapeutics Development 25
Nektar Therapeutics 25
Santen Pharmaceutical Co., Ltd. 26
Pacira Pharmaceuticals, Inc. 27
AcelRx Pharmaceuticals, Inc. 28
Laboratorios Del Dr. Esteve S.A. 29
Pfizer Inc. 30
Sigma-Tau S.p.A. 31
A. Menarini Industrie Farmaceutiche Riunite Srl 32
Anavex Life Sciences Corp. 33
Nuvo Research Inc. 34
Zalicus Inc. 35
Yungjin Pharm Ind. Co., Ltd. 36
Array BioPharma Inc. 37
Orexo AB 38
Insys Therapeutics, Inc. 39
Grunenthal GmbH 40
AngioChem Inc. 41
Charleston Laboratories, Inc. 42
Trevena, Inc. 43
Syntrix Biosystems, Inc. 44
Kineta, Inc. 45
QRxPharma Limited 46
Cara Therapeutics, Inc. 47
Iroko Pharmaceuticals, LLC 48
Encore Therapeutics Inc. 49
Madeira Therapeutics 50
MEDRx Co., Ltd. 51
Rottapharm|Madaus 52
Thar Pharmaceuticals, Inc. 53
Hanmi Pharmaceuticals, Co. Ltd. 54
Adynxx, Inc. 55
Theralpha SAS 56
ChironWells GmbH 57
Acute Pain - Therapeutics Assessment 58
Assessment by Monotherapy Products 58
Assessment by Combination Products 59
Assessment by Target 60
Assessment by Mechanism of Action 64
Assessment by Route of Administration 68
Assessment by Molecule Type 70
Drug Profiles 72
(morphine + oxycodone) IR - Drug Profile 72
indomethacin nanoformulation - Drug Profile 74
(oxycodone + acetaminophen) CR - Drug Profile 76
tapentadol - Drug Profile 77
(lidocaine + tetracaine) - Drug Profile 78
(dexketoprofen trometamol + tramadol hydrochloride) - Drug Profile 80
(etodolac + lidocaine) - Drug Profile 81
CL-108 - Drug Profile 83
MNK-155 - Drug Profile 84
CR-4056 - Drug Profile 85
tapentadol - Drug Profile 86
ARRY-797 - Drug Profile 87
(morphine + oxycodone) - Drug Profile 89
CR-845 - Drug Profile 91
alfentanil hydrochloride - Drug Profile 93
ARX-04 - Drug Profile 94
RQ-00317076 - Drug Profile 96
(aceclofenac + eperisone) - Drug Profile 97
E-58425 - Drug Profile 98
E-52862 - Drug Profile 100
AYX-1 - Drug Profile 101
immune globulin intravenous (human) - Drug Profile 102
lidocaine - Drug Profile 103
NKTR-192 - Drug Profile 104
PF-06273340 - Drug Profile 105
grapiprant - Drug Profile 106
YJAT-SR - Drug Profile 108
TRV-734 - Drug Profile 109
ANAVEX-1007 - Drug Profile 110
ANAVEX-1519 - Drug Profile 111
ANG-2002 - Drug Profile 112
Kappa Opioid Receptor Biased Ligand Program - Drug Profile 113
RQ-00000008 - Drug Profile 114
DepoNSAID ER - Drug Profile 115
ANAVEX-1066 - Drug Profile 116
THA-903 - Drug Profile 117
T-109 - Drug Profile 118
Conolidine - Drug Profile 119
buprenorphine hydrochloride ER - Drug Profile 120
FY-101C - Drug Profile 121
grapiprant - Drug Profile 122
ANAVEX-1005 - Drug Profile 124
HS-731 - Drug Profile 125
Sodium Channel Blockers - Drug Profile 126
ST-4070 - Drug Profile 127
Prostatic Acid Phosphatase - Drug Profile 128
VPX-595 - Drug Profile 129
U-2902 - Drug Profile 130
JBT-101 SR + Opioid - Drug Profile 131
Omnitram - Drug Profile 132
Drug Targeting Transforming Growth Factor-Beta - Drug Profile 133
SA-14867 - Drug Profile 134
ET-1 - Drug Profile 135
RO-656570 - Drug Profile 136
buprenorphine hydrochloride - Drug Profile 137
CR-845 - Drug Profile 138
(morphine + oxycodone) IR - Drug Profile 140
MT-003 - Drug Profile 142
RQ-00317076 - Drug Profile 143
CLHL - Drug Profile 144
CLH-5 - Drug Profile 145
CLH-10 - Drug Profile 146
Acute Pain - Recent Pipeline Updates 147
Acute Pain - Dormant Projects 164
Acute Pain - Discontinued Products 167
Acute Pain - Product Development Milestones 168
Featured News & Press Releases 168
Appendix 175
Methodology 175
Coverage 175
Secondary Research 175
Primary Research 175
Expert Panel Validation 175
Contact Us 176
Disclaimer 176
List of Tables
Number of Products under Development for Acute Pain, H1 2014 14
Number of Products under Development for Acute Pain - Comparative Analysis, H1 2014 15
Number of Products under Development by Companies, H1 2014 17
Number of Products under Development by Companies, H1 2014 (Contd..1) 18
Number of Products under Development by Companies, H1 2014 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H1 2014 20
Comparative Analysis by Late Stage Development, H1 2014 21
Comparative Analysis by Clinical Stage Development, H1 2014 22
Comparative Analysis by Early Stage Development, H1 2014 23
Comparative Analysis by Unknown Stage Development, H1 2014 24
Products under Development by Companies, H1 2014 25
Products under Development by Companies, H1 2014 (Contd..1) 26
Products under Development by Companies, H1 2014 (Contd..2) 27
Products under Investigation by Universities/Institutes, H1 2014 28
Acute Pain - Pipeline by Nektar Therapeutics, H1 2014 29
Acute Pain - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2014 30
Acute Pain - Pipeline by Pacira Pharmaceuticals, Inc., H1 2014 31
Acute Pain - Pipeline by AcelRx Pharmaceuticals, Inc., H1 2014 32
Acute Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2014 33
Acute Pain - Pipeline by Pfizer Inc., H1 2014 34
Acute Pain - Pipeline by Sigma-Tau S.p.A., H1 2014 35
Acute Pain - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2014 36
Acute Pain - Pipeline by Anavex Life Sciences Corp., H1 2014 37
Acute Pain - Pipeline by Nuvo Research Inc., H1 2014 38
Acute Pain - Pipeline by Zalicus Inc., H1 2014 39
Acute Pain - Pipeline by Yungjin Pharm Ind. Co., Ltd., H1 2014 40
Acute Pain - Pipeline by Array BioPharma Inc., H1 2014 41
Acute Pain - Pipeline by Orexo AB, H1 2014 42
Acute Pain - Pipeline by Insys Therapeutics, Inc., H1 2014 43
Acute Pain - Pipeline by Grunenthal GmbH, H1 2014 44
Acute Pain - Pipeline by AngioChem Inc., H1 2014 45
Acute Pain - Pipeline by Charleston Laboratories, Inc., H1 2014 46
Acute Pain - Pipeline by Trevena, Inc., H1 2014 47
Acute Pain - Pipeline by Syntrix Biosystems, Inc., H1 2014 48
Acute Pain - Pipeline by Kineta, Inc., H1 2014 49
Acute Pain - Pipeline by QRxPharma Limited, H1 2014 50
Acute Pain - Pipeline by Cara Therapeutics, Inc., H1 2014 51
Acute Pain - Pipeline by Iroko Pharmaceuticals, LLC, H1 2014 52
Acute Pain - Pipeline by Encore Therapeutics Inc., H1 2014 53
Acute Pain - Pipeline by Madeira Therapeutics, H1 2014 54
Acute Pain - Pipeline by MEDRx Co., Ltd., H1 2014 55
Acute Pain - Pipeline by Rottapharm|Madaus, H1 2014 56
Acute Pain - Pipeline by Thar Pharmaceuticals, Inc., H1 2014 57
Acute Pain - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2014 58
Acute Pain - Pipeline by Adynxx, Inc., H1 2014 59
Acute Pain - Pipeline by Theralpha SAS, H1 2014 60
Acute Pain - Pipeline by ChironWells GmbH, H1 2014 61
Assessment by Monotherapy Products, H1 2014 62
Assessment by Combination Products, H1 2014 63
Number of Products by Stage and Target, H1 2014 66
Number of Products by Stage and Mechanism of Action, H1 2014 70
Number of Products by Stage and Route of Administration, H1 2014 73
Number of Products by Stage and Molecule Type, H1 2014 75
Acute Pain Therapeutics - Recent Pipeline Updates, H1 2014 151
Acute Pain - Dormant Projects, H1 2014 168
Acute Pain - Dormant Projects (Contd..1), H1 2014 169
Acute Pain - Dormant Projects (Contd..2), H1 2014 170
Acute Pain - Discontinued Products, H1 2014 171
List of Figures
Number of Products under Development for Acute Pain, H1 2014 14
Number of Products under Development for Acute Pain - Comparative Analysis, H1 2014 15
Number of Products under Development by Companies, H1 2014 16
Number of Products under Investigation by Universities/Institutes, H1 2014 20
Comparative Analysis by Late Stage Development, H1 2014 21
Comparative Analysis by Clinical Stage Development, H1 2014 22
Comparative Analysis by Early Stage Products, H1 2014 23
Assessment by Monotherapy Products, H1 2014 62
Assessment by Combination Products, H1 2014 63
Number of Products by Top 10 Target, H1 2014 64
Number of Products by Stage and Top 10 Target, H1 2014 65
Number of Products by Top 10 Mechanism of Action, H1 2014 68
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 69
Number of Products by Top 10 Route of Administration, H1 2014 72
Number of Products by Stage and Top 10 Route of Administration, H1 2014 73
Number of Products by Top 10 Molecule Type, H1 2014 74
Number of Products by Stage and Top 10 Molecule Type, H1 2014 75
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Acute Pain Overview 9
Therapeutics Development 10
Pipeline Products for Acute Pain - Overview 10
Pipeline Products for Acute Pain - Comparative Analysis 11
Acute Pain - Therapeutics under Development by Companies 12
Acute Pain - Therapeutics under Investigation by Universities/Institutes 16
Acute Pain - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Acute Pain - Products under Development by Companies 21
Acute Pain - Products under Investigation by Universities/Institutes 24
Acute Pain - Companies Involved in Therapeutics Development 25
Nektar Therapeutics 25
Santen Pharmaceutical Co., Ltd. 26
Pacira Pharmaceuticals, Inc. 27
AcelRx Pharmaceuticals, Inc. 28
Laboratorios Del Dr. Esteve S.A. 29
Pfizer Inc. 30
Sigma-Tau S.p.A. 31
A. Menarini Industrie Farmaceutiche Riunite Srl 32
Anavex Life Sciences Corp. 33
Nuvo Research Inc. 34
Zalicus Inc. 35
Yungjin Pharm Ind. Co., Ltd. 36
Array BioPharma Inc. 37
Orexo AB 38
Insys Therapeutics, Inc. 39
Grunenthal GmbH 40
AngioChem Inc. 41
Charleston Laboratories, Inc. 42
Trevena, Inc. 43
Syntrix Biosystems, Inc. 44
Kineta, Inc. 45
QRxPharma Limited 46
Cara Therapeutics, Inc. 47
Iroko Pharmaceuticals, LLC 48
Encore Therapeutics Inc. 49
Madeira Therapeutics 50
MEDRx Co., Ltd. 51
Rottapharm|Madaus 52
Thar Pharmaceuticals, Inc. 53
Hanmi Pharmaceuticals, Co. Ltd. 54
Adynxx, Inc. 55
Theralpha SAS 56
ChironWells GmbH 57
Acute Pain - Therapeutics Assessment 58
Assessment by Monotherapy Products 58
Assessment by Combination Products 59
Assessment by Target 60
Assessment by Mechanism of Action 64
Assessment by Route of Administration 68
Assessment by Molecule Type 70
Drug Profiles 72
(morphine + oxycodone) IR - Drug Profile 72
indomethacin nanoformulation - Drug Profile 74
(oxycodone + acetaminophen) CR - Drug Profile 76
tapentadol - Drug Profile 77
(lidocaine + tetracaine) - Drug Profile 78
(dexketoprofen trometamol + tramadol hydrochloride) - Drug Profile 80
(etodolac + lidocaine) - Drug Profile 81
CL-108 - Drug Profile 83
MNK-155 - Drug Profile 84
CR-4056 - Drug Profile 85
tapentadol - Drug Profile 86
ARRY-797 - Drug Profile 87
(morphine + oxycodone) - Drug Profile 89
CR-845 - Drug Profile 91
alfentanil hydrochloride - Drug Profile 93
ARX-04 - Drug Profile 94
RQ-00317076 - Drug Profile 96
(aceclofenac + eperisone) - Drug Profile 97
E-58425 - Drug Profile 98
E-52862 - Drug Profile 100
AYX-1 - Drug Profile 101
immune globulin intravenous (human) - Drug Profile 102
lidocaine - Drug Profile 103
NKTR-192 - Drug Profile 104
PF-06273340 - Drug Profile 105
grapiprant - Drug Profile 106
YJAT-SR - Drug Profile 108
TRV-734 - Drug Profile 109
ANAVEX-1007 - Drug Profile 110
ANAVEX-1519 - Drug Profile 111
ANG-2002 - Drug Profile 112
Kappa Opioid Receptor Biased Ligand Program - Drug Profile 113
RQ-00000008 - Drug Profile 114
DepoNSAID ER - Drug Profile 115
ANAVEX-1066 - Drug Profile 116
THA-903 - Drug Profile 117
T-109 - Drug Profile 118
Conolidine - Drug Profile 119
buprenorphine hydrochloride ER - Drug Profile 120
FY-101C - Drug Profile 121
grapiprant - Drug Profile 122
ANAVEX-1005 - Drug Profile 124
HS-731 - Drug Profile 125
Sodium Channel Blockers - Drug Profile 126
ST-4070 - Drug Profile 127
Prostatic Acid Phosphatase - Drug Profile 128
VPX-595 - Drug Profile 129
U-2902 - Drug Profile 130
JBT-101 SR + Opioid - Drug Profile 131
Omnitram - Drug Profile 132
Drug Targeting Transforming Growth Factor-Beta - Drug Profile 133
SA-14867 - Drug Profile 134
ET-1 - Drug Profile 135
RO-656570 - Drug Profile 136
buprenorphine hydrochloride - Drug Profile 137
CR-845 - Drug Profile 138
(morphine + oxycodone) IR - Drug Profile 140
MT-003 - Drug Profile 142
RQ-00317076 - Drug Profile 143
CLHL - Drug Profile 144
CLH-5 - Drug Profile 145
CLH-10 - Drug Profile 146
Acute Pain - Recent Pipeline Updates 147
Acute Pain - Dormant Projects 164
Acute Pain - Discontinued Products 167
Acute Pain - Product Development Milestones 168
Featured News & Press Releases 168
Appendix 175
Methodology 175
Coverage 175
Secondary Research 175
Primary Research 175
Expert Panel Validation 175
Contact Us 176
Disclaimer 176
List of Tables
Number of Products under Development for Acute Pain, H1 2014 14
Number of Products under Development for Acute Pain - Comparative Analysis, H1 2014 15
Number of Products under Development by Companies, H1 2014 17
Number of Products under Development by Companies, H1 2014 (Contd..1) 18
Number of Products under Development by Companies, H1 2014 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H1 2014 20
Comparative Analysis by Late Stage Development, H1 2014 21
Comparative Analysis by Clinical Stage Development, H1 2014 22
Comparative Analysis by Early Stage Development, H1 2014 23
Comparative Analysis by Unknown Stage Development, H1 2014 24
Products under Development by Companies, H1 2014 25
Products under Development by Companies, H1 2014 (Contd..1) 26
Products under Development by Companies, H1 2014 (Contd..2) 27
Products under Investigation by Universities/Institutes, H1 2014 28
Acute Pain - Pipeline by Nektar Therapeutics, H1 2014 29
Acute Pain - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2014 30
Acute Pain - Pipeline by Pacira Pharmaceuticals, Inc., H1 2014 31
Acute Pain - Pipeline by AcelRx Pharmaceuticals, Inc., H1 2014 32
Acute Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2014 33
Acute Pain - Pipeline by Pfizer Inc., H1 2014 34
Acute Pain - Pipeline by Sigma-Tau S.p.A., H1 2014 35
Acute Pain - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2014 36
Acute Pain - Pipeline by Anavex Life Sciences Corp., H1 2014 37
Acute Pain - Pipeline by Nuvo Research Inc., H1 2014 38
Acute Pain - Pipeline by Zalicus Inc., H1 2014 39
Acute Pain - Pipeline by Yungjin Pharm Ind. Co., Ltd., H1 2014 40
Acute Pain - Pipeline by Array BioPharma Inc., H1 2014 41
Acute Pain - Pipeline by Orexo AB, H1 2014 42
Acute Pain - Pipeline by Insys Therapeutics, Inc., H1 2014 43
Acute Pain - Pipeline by Grunenthal GmbH, H1 2014 44
Acute Pain - Pipeline by AngioChem Inc., H1 2014 45
Acute Pain - Pipeline by Charleston Laboratories, Inc., H1 2014 46
Acute Pain - Pipeline by Trevena, Inc., H1 2014 47
Acute Pain - Pipeline by Syntrix Biosystems, Inc., H1 2014 48
Acute Pain - Pipeline by Kineta, Inc., H1 2014 49
Acute Pain - Pipeline by QRxPharma Limited, H1 2014 50
Acute Pain - Pipeline by Cara Therapeutics, Inc., H1 2014 51
Acute Pain - Pipeline by Iroko Pharmaceuticals, LLC, H1 2014 52
Acute Pain - Pipeline by Encore Therapeutics Inc., H1 2014 53
Acute Pain - Pipeline by Madeira Therapeutics, H1 2014 54
Acute Pain - Pipeline by MEDRx Co., Ltd., H1 2014 55
Acute Pain - Pipeline by Rottapharm|Madaus, H1 2014 56
Acute Pain - Pipeline by Thar Pharmaceuticals, Inc., H1 2014 57
Acute Pain - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2014 58
Acute Pain - Pipeline by Adynxx, Inc., H1 2014 59
Acute Pain - Pipeline by Theralpha SAS, H1 2014 60
Acute Pain - Pipeline by ChironWells GmbH, H1 2014 61
Assessment by Monotherapy Products, H1 2014 62
Assessment by Combination Products, H1 2014 63
Number of Products by Stage and Target, H1 2014 66
Number of Products by Stage and Mechanism of Action, H1 2014 70
Number of Products by Stage and Route of Administration, H1 2014 73
Number of Products by Stage and Molecule Type, H1 2014 75
Acute Pain Therapeutics - Recent Pipeline Updates, H1 2014 151
Acute Pain - Dormant Projects, H1 2014 168
Acute Pain - Dormant Projects (Contd..1), H1 2014 169
Acute Pain - Dormant Projects (Contd..2), H1 2014 170
Acute Pain - Discontinued Products, H1 2014 171
List of Figures
Number of Products under Development for Acute Pain, H1 2014 14
Number of Products under Development for Acute Pain - Comparative Analysis, H1 2014 15
Number of Products under Development by Companies, H1 2014 16
Number of Products under Investigation by Universities/Institutes, H1 2014 20
Comparative Analysis by Late Stage Development, H1 2014 21
Comparative Analysis by Clinical Stage Development, H1 2014 22
Comparative Analysis by Early Stage Products, H1 2014 23
Assessment by Monotherapy Products, H1 2014 62
Assessment by Combination Products, H1 2014 63
Number of Products by Top 10 Target, H1 2014 64
Number of Products by Stage and Top 10 Target, H1 2014 65
Number of Products by Top 10 Mechanism of Action, H1 2014 68
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 69
Number of Products by Top 10 Route of Administration, H1 2014 72
Number of Products by Stage and Top 10 Route of Administration, H1 2014 73
Number of Products by Top 10 Molecule Type, H1 2014 74
Number of Products by Stage and Top 10 Molecule Type, H1 2014 75
